Bright Minds Biosciences has stated that its management is not aware of any major changes in its operations, despite recent market activity. The company’s stock soared from a low of $0.94 on October 9 to $38.49, marking a staggering increase of 3,994.74%. In just one trading day on October 15, the stock jumped by 1,445.78%. Bright Minds is working on new treatments for complex mental health disorders, aiming to create safer and more effective drugs by improving serotonergic compounds.
About Bright Minds
Bright Minds is dedicated to developing innovative treatments for neuropsychiatric disorders, epilepsy, and pain. The company offers next-generation serotonin agonists aimed at correcting neurocircuit abnormalities linked to hard-to-treat conditions like treatment-resistant epilepsy, depression, PTSD, and chronic pain. By utilizing its expertise in science and drug development, Bright Minds aims to create safer and more effective drugs that maintain the therapeutic benefits of psychedelics and serotonergic compounds while reducing side effects compared to older treatments like fenfluramine, psilocybin, LSD, and ibogaine.
Stay informed with our financial updates, stocks, bonds, commodities. Get global & political insights. Follow us & enable notifications for the latest updates.
